ReviewMedicinal research reviews2014
Molecular biology and inhibitors of hepatitis A virus.
Review in Medicinal research reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Combination of vemurafenib, pleconaril, and AG7404 attenuates enterovirus replicationNAR molecular medicine · 2026Article
- Zinc Acetate Inhibits Hepatitis A Virus Replication: Possible Treatment for Patients with Type A Acute-on-Chronic Liver Failure.Pathogens (Basel, Switzerland) · 2025Article
- Identification of Mulberrofuran as a potent inhibitor of hepatitis A virus 3CMolecular diversity · 2024Article
- The Seroprevalence of Hepatitis A in Patients with Positive Human Immunodeficiency Virus.Middle East journal of digestive diseases · 2023Article
- Periodic Characteristics of Hepatitis Virus Infections From 2013 to 2020 and Their Association With Meteorological Factors in Guangdong, China: Surveillance Study.JMIR public health and surveillance · 2023Article
- Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment.Viruses · 2021Review
- Natural Products and Their Potential Anti-HAV Activity.Pathogens (Basel, Switzerland) · 2021Review
- Iminosugar Glucosidase Inhibitors Reduce Hepatic Inflammation in Hepatitis A Virus-InfectedJournal of virology · 2021Article
- Male-Dominant Hepatitis A Outbreak Observed among Non-HIV-Infected Persons in the Northern Part of Tokyo, Japan.Viruses · 2021Article
- Review
- Structural basis for neutralization of hepatitis A virus informs a rational design of highly potent inhibitors.PLoS biology · 2019Article
- Induction and Suppression of Innate Antiviral Responses by Hepatitis A Virus.Frontiers in microbiology · 2018Review
- The Strategy of Picornavirus Evading Host Antiviral Responses: Non-structural Proteins Suppress the Production of IFNs.Frontiers in microbiology · 2018Review
- Inhibitory effect of Japanese rice-koji miso extracts on hepatitis A virus replication in association with the elevation of glucose-regulated protein 78 expression.International journal of medical sciences · 2018Article
- CXCL10 is produced in hepatitis A virus-infected cells in an IRF3-dependent but IFN-independent manner.Scientific reports · 2017Article
- Hepatitis A virus genotype IA-infected patient with marked elevation of aspartate aminotransferase levels.Clinical journal of gastroenterology · 2017Article
- Hepatitis A virus-encoded miRNAs attenuate the accumulation of viral genomic RNAs in infected cells.Virus genes · 2016Article
- Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus.Journal of clinical and translational hepatology · 2015Review
- Suppression of La antigen exerts potential antiviral effects against hepatitis A virus.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis A virus (HAV) is a faeco-orally transmitted picornavirus and is one of the main causes of acute hepatitis worldwide. An overview of the molecular biology of HAV is presented with an emphasis on recent findings. Immune evasion strategies and a possible correlation between HAV and atopy are discussed as well. Despite the availability of efficient vaccines, antiviral drugs targeting HAV are required to treat severe cases of fulminant hepatitis, contain outbreaks, and halt the potential spread of vaccine-escape variants. Additionally, such drugs could be used to shorten the period of illness and decrease associated economical costs. Several known inhibitors of HAV with various mechanisms of action will be discussed. Since none of these molecules is readily useable in the clinic and since the availability of an anti-HAV drug would be of clinical importance, increased efforts should be targeted toward discovery and development of such antivirals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.